GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...

The pharmaceutical company citied promising pipeline developments and said cancer treatments drove above-expected growth.

GSK Plc announced a share buyback of £2 billion as it saw better than expected profit in the fourth quarter. The share ...

GSK PLC closed 24.32% short of its 52-week high of £18.24, which the company achieved on May 16th.

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

GSK said pretax profit in 2024 fell 43% to GBP3.48 billion from GBP6.06 billion a year prior, though revenue increased 3.5% to GBP31.38 billion from GBP30.33 billion, ahead of the GBP31.05 billion ...

GSK (GSK.L, GSK) reported fiscal 2024 profit before tax of 3.5 billion pounds, down 43% at AER, or down 34% at CER from prior year.

CORE EARNINGS PER SHARE FORECAST: Fourth-quarter core earnings per share is expected to fall to 20.6 pounds from 28.9 pounds the year earlier, according to Visible Alpha. Shares in GSK are 3.6% up ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.